Undated, Mar 20: Amgen Inc said its experimental andnovel treatment for advanced melanoma met the main goal of a late-stage clinical trial by demonstrating a durable response in significantly more patients than a comparison treatment. The drug known as talimogene laherparepvec induced a durable response rate (DRR) – defined as a complete or partial tumor shrinkage lasting for at least six months – in 16 percent of patients, according to preliminary results. (agencies)
Trending Now
E-Paper
Follow our WhatsApp channel